There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., ...
– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...
Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million ...
– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...
Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast. Idiopathic pulmonary ...
The FDA has approved the topical phosphodiesterase 4 (PDE4) inhibitor difamilast (Adquey) as a new option for mild/moderate atopic dermatitis (AD). The approval allows for use in adults and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results